Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Las Vegas Sands Corp. (LVS) Price & Performance

BridgeBio Pharma IncTrade
Las Vegas Sands Corp.Trade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Las Vegas Sands Corp. — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Las Vegas Sands Corp. trades at $45.83 (market cap $29.44B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOLVS
Market Cap
$16.36B$29.44B
Sector
HealthConsumer Cyclical
52-Week High
$90.17$69.49
52-Week Low
$47.29$44.78
Enterprise Value
$18.14B$41.33B
Dividend Yield
2.64%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Las Vegas Sands Corp.

Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.

Read more on LVS